Fate Therapeutics Inc (NASDAQ: FATE) on Monday, soared 2.88% from the previous trading day, before settling in for the closing price of $1.04. Within the past 52 weeks, FATE’s price has moved between $0.66 and $5.92.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 46.37% over the last five years. The company achieved an average annual earnings per share of 7.36%. With a float of $103.49 million, this company’s outstanding shares have now reached $113.93 million.
The firm has a total of 181 workers. Let’s measure their productivity. In terms of profitability, gross margin is -189.23%, operating margin of -1542.63%, and the pretax margin is -1366.46%.
Fate Therapeutics Inc (FATE) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Fate Therapeutics Inc is 9.70%, while institutional ownership is 84.81%. The most recent insider transaction that took place on Mar 06 ’25, was worth 104,881. Before that another transaction happened on Jan 10 ’25, when Company’s insider sold 5,980 for $1.55, making the entire transaction worth $9,269. This insider now owns 270,203 shares in total.
Fate Therapeutics Inc (FATE) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.38 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.78% during the next five years compared to -2.63% drop over the previous five years of trading.
Fate Therapeutics Inc (NASDAQ: FATE) Trading Performance Indicators
Fate Therapeutics Inc (FATE) is currently performing well based on its current performance indicators. A quick ratio of 7.58 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.65, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Fate Therapeutics Inc (FATE)
Analysing the last 5-days average volume posted by the [Fate Therapeutics Inc, FATE], we can find that recorded value of 2.28 million was lower than the volume posted last year of 2.3 million. As of the previous 9 days, the stock’s Stochastic %D was 31.77%. Additionally, its Average True Range was 0.14.
During the past 100 days, Fate Therapeutics Inc’s (FATE) raw stochastic average was set at 29.13%, which indicates a significant increase from 27.57% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 114.13% in the past 14 days, which was higher than the 110.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0116, while its 200-day Moving Average is $2.2441. Now, the first resistance to watch is $1.1650. This is followed by the second major resistance level at $1.2600. The third major resistance level sits at $1.3200. If the price goes on to break the first support level at $1.0100, it is likely to go to the next support level at $0.9500. Now, if the price goes above the second support level, the third support stands at $0.8550.
Fate Therapeutics Inc (NASDAQ: FATE) Key Stats
Market capitalization of the company is 122.63 million based on 114,604K outstanding shares. Right now, sales total 13,630 K and income totals -186,260 K. The company made 1,860 K in profit during its latest quarter, and -52,150 K in sales during its previous quarter.
